Clinical trials on T-Cell Acute Lymphoblastic Leukemia

  • CT-EU-00111625

    Exploring the Safety of Donor-Derived CD5 CAR T Cells for Relapsed T-Cell Leukemia

    This clinical trial is a first-of-its-kind study designed to explore a new treatment for individuals with T-Cell Acute Lymphoblastic Leukemia that has not responded to previous treatments. The focus of this study is on a special kind of therapy called CD5 CAR T cells. These are special cells that are designed to target and fight the leukemia cells in your body.

    The study is being conducted at a single center and is open to anyone who meets the criteria, with plans to enroll at least 18 participants. Before you receive the CD5 CAR T cells, you will undergo a preparation process called lymphodepletion. This involves receiving medications called fludarabine and cyclophosphamide for 3 days to prepare your body for the CAR T cells. The exact doses of these medications will depend on whether the CAR T cells are coming from a previous donor or a new one.

    The treatment itself involves receiving the CD5 CAR T cells through an intravenous injection. The dose of CAR T cells you receive will be carefully calculated based on the results from earlier participants, starting with a lower dose and potentially moving to a higher dose if it is safe to do so.

    The main goals of this study are to understand how safe this treatment is and what side effects it might have. Specifically, the doctors will be looking at the types of side effects that occur within 21 days after the injection and any other adverse effects that happen within 30 days.

    This trial represents a hopeful step forward in the treatment of T-Cell Acute Lymphoblastic Leukemia, offering a new potential option for those who have not had success with other treatments.